From 1 April itraconazole 50 micrograms (Lozanoc) is PBS listed (Authority Required – Streamlined) for the management of systemic fungal infections.1 This listing is in line with the currently listed itraconazole 100 microgram (Sporanox) capsule for fungal infections.1
Lozanoc capsules have higher bioavailability than the currently available itraconazole capsule.2 Pharmacokinetic studies have shown that the 50 microgram Lozanoc capsules can be considered therapeutically equivalent to the 100 microgram Sporanox capsules.2
If switching patients to Lozanoc, GPs should ensure that patients are aware of their new dosing regimen and their new itraconazole brand.
PBS listing for systemic mycoses only
Itraconazole 50 and 100 microgram are approved by the Therapeutic Goods Administration for superficial and systemic mycoses. However, the PBS listing is for the following systemic mycoses only:1
systemic aspergillosis
systemic sporotrichosis
systemic histoplasmosis
disseminated and chronic pulmonary histoplasmosis infection
oropharyngeal or oesophageal candidiasis.
Itraconazole is not PBS listed for superficial mycoses.
Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer. This website uses cookies. Read our privacy policy.
